Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Certara, Inc. (CERT:NASDAQ), powered by AI.
Certara, Inc. is currently trading at $5.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Certara, Inc. on Alpha Lenz.
Certara, Inc.'s P/E ratio is -522.9.
“Certara, Inc. trades at a P/E of -522.9 (undervalued) with modest ROE of -0.2%.”
Ask for details →Certara Inc. is a prominent player in the biopharmaceutical industry, specializing in biosimulation and regulatory software to accelerate drug discovery, development, and approval processes. Its primary function is to provide advanced technology solutions that streamline the journey of potential therapies from laboratory to market. Certara offers sophisticated modeling and simulation software that assists pharmaceutical companies in predicting drug behavior and efficacy, thereby enhancing decision-making and reducing development costs. Notable features of Certara’s offerings include its comprehensive suite of platforms like Simcyp and Phoenix, which are widely adopted for pharmacokinetic/pharmacodynamic (PK/PD) modeling and clinical trial analysis. The company serves a critical role in the life sciences sector by helping to bring new medicines to patients more efficiently. Certara’s impact is significant as it actively collaborates with major pharmaceutical and biotech companies globally, solidifying its position as a vital contributor to the advancement of healthcare and therapeutic innovation.
“Certara, Inc. trades at a P/E of -522.9 (undervalued) with modest ROE of -0.2%.”
Ask for details →Certara, Inc. (ticker: CERT) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 1,487 employees. Market cap is $834M.
The current price is $5.2 with a P/E ratio of -522.92x and P/B of 0.78x.
ROE is -0.15% and operating margin is 5.02%. Annual revenue is $419M.